Group B Streptococcus
12
1
1
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
8.3%
1 terminated out of 12 trials
87.5%
+1.0% vs benchmark
0%
0 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (12)
Preparing for Maternal GBS Vaccine Trials in Africa
Comprehensive Outcomes Monitoring for Peri- and Postnatal Invasive Group B Strep Sequelae (COMPPASS) Registry
The Prevalence of Group B Streptococcus Positive Pregnant Patients in an Inner City Tertiary Care Center
Intrapartum Rapid GBS Testing in Patients Presenting With Threatened Preterm Labor
Developing a Controlled Human Infection Model for Group B Streptococcus (CHIM_GBS)
Group B Streptococcus: Attitudes to Immunisation in Pregnancy
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women
Oral Penicillin and Penicillin Levels in Venous Umbilical Cord Blood
Membrane Sweeping in Group B Streptococcus (GBS) Positive Patients
Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines
Group B Streptococcus (GBS) Polymerase Chain Reaction (PCR) Concordance Study
Management of Infants Born to Group B Streptococcus Positive Mothers.